Eli Lilly & Company (NYSE:LLY) ranks among the best non-tech stocks to buy according to billionaires. Eli Lilly & Company’s Alzheimer’s therapy Kisunla received approval from the US Food and Drug Administration on July 9 for a label update that included a new recommended titration dose schedule.
When compared to the initial dose plan, the adjusted donanemab-azbt titration schedule substantially lowered the incidence of amyloid-related imaging abnormalities with edema/effusion (ARIA-E). The updated schedule maintained comparable levels of amyloid plaque removal while reducing ARIA-E rates by 41% at 24 weeks and 35% at 52 weeks.
The FDA first authorized Kisunla back in July 2024 based on evidence from the TRAILBLAZER-ALZ 2 Phase 3 clinical trial, which showed the medication reduced cognitive and functional deterioration in people with early-stage Alzheimer’s.
Eli Lilly & Company is a major global pharmaceutical company that develops, manufactures, and distributes an assortment of medications. Founded in 1876, it has evolved into one of the world’s largest pharmaceutical companies.
Read More: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds
